GFI1 and acute myeloid leukemia: For our analysis, we took the same data set as described by Verhaak et al. 19 and compared survival outcomes for the whole cohort with those for patients with CN-AML, distinguishing patients with low or high expression of GFI1. Our CN-AML category (n = 178) excluded patients displaying abnormal or unknown karyotype or classified in the M3 FAB subgroup, as those patients are treated differently.